Track topics on Twitter Track topics that are important to you
Eribulin mesylate (Halaven; Eisai) - a synthetic analogue of the marine natural product halichondrin B that interferes with microtubule dynamics - was approved in November 2010 by the US Food and Drug Administration for the treatment of metastatic breast cancer.
Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
This article was published in the following journal.
Name: Nature reviews. Drug discovery
Treatment of advanced ovarian cancer involves platinum-based chemotherapy. However, chemoresistance is a major obstacle. Cancer stem cells (CSCs) are thought to be one of the causes of chemoresistance...
ABSTRACT Aim: This multicenter study describes the effectiveness of eribulin in current practice. Patients & methods: In total, 78 patients with advanced metastatic breast cancer, previously treate...
Data from two phase 3 studies of eribulin were pooled in analyses initially requested by the European Medicines Agency to assess whether specific patient subgroups, previously treated with an anthracy...
ABSTRACT Microtubule antagonists are highly active agents for treatment of metastatic lung cancer, but can lead to significant toxicities and tumor resistance. Eribulin mesylate is a novel antimicr...
Backgrounds. Eribulin is a non-taxane, microtubule dynamics inhibitor approved for the treatment of patients with metastatic breast cancer (MBC) in Europe in March 2011. Material and methods. For the ...
This phase II trial studies how well eribulin mesylate works in treating patients with osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment (refrac...
This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in...
The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval a...
This pilot trial studies the concentration of eribulin mesylate in the brain of patients with breast, bladder, or non-small cell lung cancer that has spread to the brain (metastases). Drug...
This phase I/II trial studies the side effects and best dose of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby ...
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.